DPA
PDLI

Delphi Private Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Delphi Private Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2
Closed – – 463
2015
Q4 		$0 Buy
+2
New +$8 ﹤0.01% 455

Other funds holding PDLI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Delphi Private Advisors's PDLI Position: Q1 2016 in Review

Delphi Private Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 2 shares.

Delphi Private Advisors first reported a position in PDLI in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

  • Delphi Private Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
  • Delphi Private Advisors sold 2 PDL BioPharma, Inc. shares in Q1 2016.
  • Delphi Private Advisors first reported a position in PDL BioPharma, Inc. in Q4 2015 and held it in 1 quarter.
  • Delphi Private Advisors's PDL BioPharma, Inc. position peaked at $0 in Q4 2015.
  • 195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Delphi Private Advisors's 13F filing for Q1 2016, filed 12 Aug 2016.